TY - JOUR
T1 - Unmet needs of children with peanut allergy
T2 - Aligning the risks and the evidence
AU - Chan, Edmond S.
AU - Dinakar, Chitra
AU - Gonzales-Reyes, Erika
AU - Green, Todd D.
AU - Gupta, Ruchi
AU - Jones, Douglas
AU - Wang, Julie
AU - Winders, Tonya
AU - Greenhawt, Matthew
N1 - Funding Information:
Disclosures: Dr Chan has received research support from DBV Technologies; has been a member of advisory boards for Leo Pharma, Kaléo, Pediapharm, and Pfizer; is a member of the scientific advisory board for Food Allergy Canada; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)–sponsored Guidelines for Peanut Allergy Prevention; and is colead of the Canadian Society of Allergy and Clinical Immunology oral immunotherapy guidelines. Dr Dinakar has received unrestricted research grant support from DBV and the American Association of Allergists and Immunologists of Indian Origin and honorarium from Propeller Health and the American College of Allergy, Asthma, and Immunology (editorial stipend for AllergyWatch). Dr Gonzales-Reyes is a speaker for GSK and Novarits and has participated in pharmaceutical clinical trials funded by A=Z, DBV, Genentech, GSK, HAL Allergy, and Teva. Dr Green is a full-time employee of DBV. Dr. Greenhawt is supported by grant 5K08HS024599-02 from the Agency for Healthcare Research and Quality; is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, Allergenis, Aravax, Prota, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma, and Immunology, and the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. Dr Gupta has received grants from Aimmune, Genentech, National Confectioners Association, National Institutes of Health, Rho, Stanford Sean N. Parker Center for Allergy = Asthma Research, Thermo Fisher Scientific, and UnitedHealth Group and serves as a medical consultant/advisor for Aimmune, Before Brands, DBV, DOTS Technology, Food Allergy Research = Education, Genentech, Institute for Clinical and Economic Review, and Kaléo. Dr Jones has served as a consultant for Takeda, Pharming, and Biocryst and is on the speaker's bureaus of Takeda and Pharming for other disease areas. Dr.Wang has received research support from Aimmune, DBV, NIAID, and Regeneron; consultancy fees from ALK-Abelló and DBV; and royalties from UpToDate. Ms Winders’ is employed by the Allergy = Asthma Network, which has received funding from DBV and Aimmune to promote education and awareness in peanut allergy. Funding Source: This work was sponsored by Allergy = Asthma Network and funded by DVB Technologies.
Funding Information:
Disclosures: Dr Chan has received research support from DBV Technologies; has been a member of advisory boards for Leo Pharma, Kaléo, Pediapharm, and Pfizer; is a member of the scientific advisory board for Food Allergy Canada; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases ( NIAID )–sponsored Guidelines for Peanut Allergy Prevention; and is colead of the Canadian Society of Allergy and Clinical Immunology oral immunotherapy guidelines. Dr Dinakar has received unrestricted research grant support from DBV and the American Association of Allergists and Immunologists of Indian Origin and honorarium from Propeller Health and the American College of Allergy, Asthma, and Immunology (editorial stipend for AllergyWatch). Dr Gonzales-Reyes is a speaker for GSK and Novarits and has participated in pharmaceutical clinical trials funded by A&Z, DBV , Genentech , GSK , HAL Allergy, and Teva. Dr Green is a full-time employee of DBV. Dr. Greenhawt is supported by grant 5K08HS024599-02 from the Agency for Healthcare Research and Quality; is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV , Sanofi / Genzyme , Genentech , Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, Allergenis, Aravax, Prota, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV , Before Brands, multiple state allergy societies, the American College of Allergy, Asthma, and Immunology, and the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. Dr Gupta has received grants from Aimmune, Genentech , National Confectioners Association, National Institutes of Health , Rho, Stanford Sean N. Parker Center for Allergy & Asthma Research, Thermo Fisher Scientific, and UnitedHealth Group and serves as a medical consultant/advisor for Aimmune, Before Brands, DBV, DOTS Technology, Food Allergy Research & Education, Genentech, Institute for Clinical and Economic Review, and Kaléo. Dr Jones has served as a consultant for Takeda, Pharming, and Biocryst and is on the speaker’s bureaus of Takeda and Pharming for other disease areas. Dr.Wang has received research support from Aimmune, DBV, NIAID, and Regeneron; consultancy fees from ALK-Abelló and DBV; and royalties from UpToDate. Ms Winders’ is employed by the Allergy & Asthma Network, which has received funding from DBV and Aimmune to promote education and awareness in peanut allergy.
Funding Information:
Funding Source: This work was sponsored by Allergy & Asthma Network and funded by DVB Technologies.
Publisher Copyright:
© 2020 The Authors
PY - 2020/5
Y1 - 2020/5
N2 - Background: Peanut allergy is a potentially severe and lifelong allergy, with few effective treatments or preventive measures. Objective: To convene an expert panel of allergists, pediatricians, and advocates to discuss and highlight unmet needs in the prevention and management of peanut allergies. Methods: Literature searches of PubMed were performed. The panel evaluated published data on the prevention of peanut allergy, treatment of existing peanut allergy, and management of reactions after unintentional peanut exposures. Results: The following key unmet needs in the prevention and management of peanut allergy were identified: (1) enhancing and optimizing implementation of early peanut introduction as a means of preventing the development of peanut allergy, (2) developing knowledge translation strategies regarding the safety and efficacy data for current and emerging immunotherapies for peanut-allergic children to support their use in clinical practice, and (3) promoting understanding of true exposure risk in allergic individuals and ensuring access to epinephrine for unintentional exposures that provoke severe reactions. Practitioners should help educate caregivers about the actual risks associated with peanut allergy and its prevention and management so that treatment decisions can be evidence based rather than fear based. Support tools are needed to help address caregiver goals, expectations, and psychological barriers, as well as identify facilitators for prevention and treatment strategies. Conclusion: There are significant unmet needs in our understanding of peanut allergy; addressing these needs will help to enhance understanding of how to most effectively prevent and treat peanut allergy, as well as educate the food-allergic and nonallergic community regarding current evidence-based practices.
AB - Background: Peanut allergy is a potentially severe and lifelong allergy, with few effective treatments or preventive measures. Objective: To convene an expert panel of allergists, pediatricians, and advocates to discuss and highlight unmet needs in the prevention and management of peanut allergies. Methods: Literature searches of PubMed were performed. The panel evaluated published data on the prevention of peanut allergy, treatment of existing peanut allergy, and management of reactions after unintentional peanut exposures. Results: The following key unmet needs in the prevention and management of peanut allergy were identified: (1) enhancing and optimizing implementation of early peanut introduction as a means of preventing the development of peanut allergy, (2) developing knowledge translation strategies regarding the safety and efficacy data for current and emerging immunotherapies for peanut-allergic children to support their use in clinical practice, and (3) promoting understanding of true exposure risk in allergic individuals and ensuring access to epinephrine for unintentional exposures that provoke severe reactions. Practitioners should help educate caregivers about the actual risks associated with peanut allergy and its prevention and management so that treatment decisions can be evidence based rather than fear based. Support tools are needed to help address caregiver goals, expectations, and psychological barriers, as well as identify facilitators for prevention and treatment strategies. Conclusion: There are significant unmet needs in our understanding of peanut allergy; addressing these needs will help to enhance understanding of how to most effectively prevent and treat peanut allergy, as well as educate the food-allergic and nonallergic community regarding current evidence-based practices.
UR - http://www.scopus.com/inward/record.url?scp=85079873721&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2020.01.016
DO - 10.1016/j.anai.2020.01.016
M3 - Article
C2 - 32007568
AN - SCOPUS:85079873721
VL - 124
SP - 479
EP - 486
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
SN - 1081-1206
IS - 5
ER -